MA52284A - Anticorps anti-hla-g et leur utilisation - Google Patents

Anticorps anti-hla-g et leur utilisation

Info

Publication number
MA52284A
MA52284A MA052284A MA52284A MA52284A MA 52284 A MA52284 A MA 52284A MA 052284 A MA052284 A MA 052284A MA 52284 A MA52284 A MA 52284A MA 52284 A MA52284 A MA 52284A
Authority
MA
Morocco
Prior art keywords
hla
antibodies
Prior art date
Application number
MA052284A
Other languages
English (en)
Inventor
Alexander Bujotzek
Stefan Dengl
Sebastian Fenn
Jens Fischer
Andreas Hinz
Sabine Hoves
Claudia Kirstenpfad
Stefan Klostermann
Meher Majety
Joerg Moelleken
Georg Tiefenthaler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52284A publication Critical patent/MA52284A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MA052284A 2018-04-18 2019-04-17 Anticorps anti-hla-g et leur utilisation MA52284A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18168011 2018-04-18

Publications (1)

Publication Number Publication Date
MA52284A true MA52284A (fr) 2021-02-24

Family

ID=62025723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052284A MA52284A (fr) 2018-04-18 2019-04-17 Anticorps anti-hla-g et leur utilisation

Country Status (20)

Country Link
US (1) US20210147553A1 (fr)
EP (1) EP3781593A1 (fr)
JP (1) JP7186239B2 (fr)
KR (1) KR102608672B1 (fr)
CN (1) CN112004831B (fr)
AR (1) AR114789A1 (fr)
AU (1) AU2019254596A1 (fr)
BR (1) BR112020020588A2 (fr)
CA (1) CA3094895A1 (fr)
CL (1) CL2020002540A1 (fr)
CO (1) CO2020012347A2 (fr)
CR (1) CR20200483A (fr)
IL (1) IL277308A (fr)
MA (1) MA52284A (fr)
MX (1) MX2020010951A (fr)
PE (1) PE20201419A1 (fr)
SG (1) SG11202009695QA (fr)
TW (1) TW201945395A (fr)
WO (1) WO2019202040A1 (fr)
ZA (1) ZA202006066B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820904A2 (fr) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Anticorps se liant à ilt4
SG11202103104RA (en) 2018-09-27 2021-04-29 Tizona Therapeutics Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
CN113528448B (zh) * 2020-04-14 2023-01-24 同济大学 一种人胚胎干细胞的构建方法
EP4263609A1 (fr) 2020-12-17 2023-10-25 F. Hoffmann-La Roche AG Anticorps anti-hla-g et leur utilisation
US20220306747A1 (en) * 2021-03-24 2022-09-29 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023182861A1 (fr) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 Récepteur antigénique chimérique anti-hla-g et son utilisation
WO2023182866A1 (fr) * 2022-03-25 2023-09-28 에이치케이이노엔 주식회사 Anticorps spécifique de hla-g et son utilisation
CN115894687A (zh) * 2022-03-31 2023-04-04 台州恩泽医疗中心(集团) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2385347C (fr) 1999-10-04 2009-12-15 Medicago Inc. Methode de regulation de la transcription des genes etrangers
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001044463A1 (fr) 1999-12-15 2001-06-21 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
WO2002034290A2 (fr) 2000-10-23 2002-05-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps et autres ligands dirige contre le recepteur de kir2dl4 pour la production de l'interferon gamma
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (fr) 2002-12-16 2008-07-16 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
WO2004065416A2 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007056441A2 (fr) 2005-11-07 2007-05-18 Genentech, Inc. Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2414391B1 (fr) 2009-04-02 2018-11-28 Roche Glycart AG Anticorps multispécifiques renfermant des anticorps complets et des fragments fab monocaténaires
WO2010115589A1 (fr) 2009-04-07 2010-10-14 Roche Glycart Ag Anticorps trivalents bispécifiques
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
EP2609112B1 (fr) 2010-08-24 2017-11-22 Roche Glycart AG Anticorps bispécifique et activable
WO2012025530A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
CN103781801B (zh) 2011-08-23 2018-02-09 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
DK2748202T3 (en) 2011-08-23 2018-09-17 Roche Glycart Ag BISPECIFIC ANTI-BINDING MOLECULES
WO2013164325A1 (fr) 2012-05-02 2013-11-07 F. Hoffmann-La Roche Ag Protéines de liaison à un antigène multispécifiques
EP2855531A1 (fr) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Anticorps multispécifiques
EP2730588A1 (fr) * 2012-11-12 2014-05-14 Intelectys Anticorps et fragments de ceux-ci dirigés contre le domaine alpha-3 de protéine HLA-G, procédés et moyens pour leur préparation et leurs utilisations
WO2015130766A1 (fr) * 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Protéines se liant a l'antigène spécifiques du peptide de la tumeur de wilms 1 restreint à hla-a2
KR20220025946A (ko) * 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
AP2017009765A0 (en) * 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
TWI805109B (zh) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
MX2017004001A (es) 2014-10-24 2017-06-30 Hoffmann La Roche Humanizacion de anticuerpos a base de angulo de interdominio de cadena pesada-cadena ligera (vh-vl).
JP7034950B2 (ja) * 2016-06-03 2022-03-14 アンヴェクティ 抗ｈｌａ－ｇ特異的抗体
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
KR102328496B1 (ko) 2017-04-07 2021-11-17 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 무선 충전 시스템, 장치, 방법 및 충전 대기 기기

Also Published As

Publication number Publication date
SG11202009695QA (en) 2020-11-27
CA3094895A1 (fr) 2019-10-24
ZA202006066B (en) 2021-09-29
KR102608672B1 (ko) 2023-11-30
IL277308A (en) 2020-10-29
PE20201419A1 (es) 2020-12-09
AU2019254596A1 (en) 2020-10-29
CL2020002540A1 (es) 2021-01-22
KR20210005080A (ko) 2021-01-13
CO2020012347A2 (es) 2020-10-30
MX2020010951A (es) 2020-11-09
US20210147553A1 (en) 2021-05-20
JP7186239B2 (ja) 2022-12-08
JP2021521791A (ja) 2021-08-30
TW201945395A (zh) 2019-12-01
BR112020020588A2 (pt) 2021-01-12
CN112004831A (zh) 2020-11-27
WO2019202040A1 (fr) 2019-10-24
AR114789A1 (es) 2020-10-14
EP3781593A1 (fr) 2021-02-24
CN112004831B (zh) 2024-04-09
CR20200483A (es) 2020-11-17

Similar Documents

Publication Publication Date Title
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA53434A (fr) Anticorps anti-tigit
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA52884A (fr) Anticorps anti-il-11
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
MA52366A (fr) Anticorps anti-tl1a optimisés
MA45543A (fr) Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
MA52152A (fr) Anticorps